The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists

Jeong Hee Choi, Hae Sim Park, Kwan Ho Lee, Jae Jeong Shim, Soo Taek Uh, Sang Pyo Lee, Yong Chul Lee, Won Il Choi, Joo In Kim, Jae Ho Lee, Myung Goo Lee, Ki Suck Jung

Research output: Contribution to journalArticle

Abstract

Backgrounds: Although glucocorticoids are one of the most potent anti-inflammatory agents, they have limited effect on cysteinyl leukotriene biosynthesis. In addition, the response to inhaled corticosteroids (ICS) and inhaled long-acting β2-agonists (LABA) combination therapy in moderate to severe persistent asthmatics varies. Additional therapy with leukotriene receptor antagonists (LTRA) in patients with moderate to severe asthma suboptimally controlled with ICS and LABA combination therapy would be complementary to asthma control. Methods: One hundred and ninety eight asthmatics entered a 2 month, open-label descriptive study. Patients suffering from persistent asthma and suboptimally controlled on a combination therapy of fluticasone/salmeterol or budesonide/formoterol were given montelukast 10 mg daily as an add-on therapy. The level of asthma control was assessed using the Asthma Control Questionnaire (ACQ) including FEV1 % predicted at the baseline and after a 2-month treatment with montelukast. A global evaluation of the treatment was also made by the patients and physicians. Results: The mean ACQ score decreased significantly on montelukast (11.5±5.4 at baseline vs. 6.7±5.0), with a significant improvement in all individual symptom scores (p<0.01). The FEV1 % predicted values did not show any significant change. 59.9% of patients and 59.4% of physicians reported global improvement in their asthma (κ=0.85). Conclusion: These results suggest that the addition of montelukast in patients with persistent asthma that is suboptimally contolled by combination therapy of ICS and LABA might confer complementary effects on asthma control.

Original languageEnglish
Pages (from-to)337-345
Number of pages9
JournalTuberculosis and Respiratory Diseases
Volume63
Issue number4
Publication statusPublished - 2007 Oct 1
Externally publishedYes

Fingerprint

montelukast
Adrenal Cortex Hormones
Asthma
Therapeutics
Physicians
Leukotriene Antagonists
Budesonide

Keywords

  • Asthma control
  • Inhaled glucocorticosteroid
  • Long-acting inhaled β2-agonist
  • Montelukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists. / Choi, Jeong Hee; Park, Hae Sim; Lee, Kwan Ho; Shim, Jae Jeong; Uh, Soo Taek; Lee, Sang Pyo; Lee, Yong Chul; Choi, Won Il; Kim, Joo In; Lee, Jae Ho; Lee, Myung Goo; Jung, Ki Suck.

In: Tuberculosis and Respiratory Diseases, Vol. 63, No. 4, 01.10.2007, p. 337-345.

Research output: Contribution to journalArticle

Choi, JH, Park, HS, Lee, KH, Shim, JJ, Uh, ST, Lee, SP, Lee, YC, Choi, WI, Kim, JI, Lee, JH, Lee, MG & Jung, KS 2007, 'The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists', Tuberculosis and Respiratory Diseases, vol. 63, no. 4, pp. 337-345.
Choi, Jeong Hee ; Park, Hae Sim ; Lee, Kwan Ho ; Shim, Jae Jeong ; Uh, Soo Taek ; Lee, Sang Pyo ; Lee, Yong Chul ; Choi, Won Il ; Kim, Joo In ; Lee, Jae Ho ; Lee, Myung Goo ; Jung, Ki Suck. / The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists. In: Tuberculosis and Respiratory Diseases. 2007 ; Vol. 63, No. 4. pp. 337-345.
@article{a13b8a919c994202bd83d390124f72a1,
title = "The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists",
abstract = "Backgrounds: Although glucocorticoids are one of the most potent anti-inflammatory agents, they have limited effect on cysteinyl leukotriene biosynthesis. In addition, the response to inhaled corticosteroids (ICS) and inhaled long-acting β2-agonists (LABA) combination therapy in moderate to severe persistent asthmatics varies. Additional therapy with leukotriene receptor antagonists (LTRA) in patients with moderate to severe asthma suboptimally controlled with ICS and LABA combination therapy would be complementary to asthma control. Methods: One hundred and ninety eight asthmatics entered a 2 month, open-label descriptive study. Patients suffering from persistent asthma and suboptimally controlled on a combination therapy of fluticasone/salmeterol or budesonide/formoterol were given montelukast 10 mg daily as an add-on therapy. The level of asthma control was assessed using the Asthma Control Questionnaire (ACQ) including FEV1 {\%} predicted at the baseline and after a 2-month treatment with montelukast. A global evaluation of the treatment was also made by the patients and physicians. Results: The mean ACQ score decreased significantly on montelukast (11.5±5.4 at baseline vs. 6.7±5.0), with a significant improvement in all individual symptom scores (p<0.01). The FEV1 {\%} predicted values did not show any significant change. 59.9{\%} of patients and 59.4{\%} of physicians reported global improvement in their asthma (κ=0.85). Conclusion: These results suggest that the addition of montelukast in patients with persistent asthma that is suboptimally contolled by combination therapy of ICS and LABA might confer complementary effects on asthma control.",
keywords = "Asthma control, Inhaled glucocorticosteroid, Long-acting inhaled β2-agonist, Montelukast",
author = "Choi, {Jeong Hee} and Park, {Hae Sim} and Lee, {Kwan Ho} and Shim, {Jae Jeong} and Uh, {Soo Taek} and Lee, {Sang Pyo} and Lee, {Yong Chul} and Choi, {Won Il} and Kim, {Joo In} and Lee, {Jae Ho} and Lee, {Myung Goo} and Jung, {Ki Suck}",
year = "2007",
month = "10",
day = "1",
language = "English",
volume = "63",
pages = "337--345",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "4",

}

TY - JOUR

T1 - The efficacy of added montelukast in persistent asthmatics who were not completely controlled on inhaled corticosteroids and inhaled long-acting β2-agonists

AU - Choi, Jeong Hee

AU - Park, Hae Sim

AU - Lee, Kwan Ho

AU - Shim, Jae Jeong

AU - Uh, Soo Taek

AU - Lee, Sang Pyo

AU - Lee, Yong Chul

AU - Choi, Won Il

AU - Kim, Joo In

AU - Lee, Jae Ho

AU - Lee, Myung Goo

AU - Jung, Ki Suck

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Backgrounds: Although glucocorticoids are one of the most potent anti-inflammatory agents, they have limited effect on cysteinyl leukotriene biosynthesis. In addition, the response to inhaled corticosteroids (ICS) and inhaled long-acting β2-agonists (LABA) combination therapy in moderate to severe persistent asthmatics varies. Additional therapy with leukotriene receptor antagonists (LTRA) in patients with moderate to severe asthma suboptimally controlled with ICS and LABA combination therapy would be complementary to asthma control. Methods: One hundred and ninety eight asthmatics entered a 2 month, open-label descriptive study. Patients suffering from persistent asthma and suboptimally controlled on a combination therapy of fluticasone/salmeterol or budesonide/formoterol were given montelukast 10 mg daily as an add-on therapy. The level of asthma control was assessed using the Asthma Control Questionnaire (ACQ) including FEV1 % predicted at the baseline and after a 2-month treatment with montelukast. A global evaluation of the treatment was also made by the patients and physicians. Results: The mean ACQ score decreased significantly on montelukast (11.5±5.4 at baseline vs. 6.7±5.0), with a significant improvement in all individual symptom scores (p<0.01). The FEV1 % predicted values did not show any significant change. 59.9% of patients and 59.4% of physicians reported global improvement in their asthma (κ=0.85). Conclusion: These results suggest that the addition of montelukast in patients with persistent asthma that is suboptimally contolled by combination therapy of ICS and LABA might confer complementary effects on asthma control.

AB - Backgrounds: Although glucocorticoids are one of the most potent anti-inflammatory agents, they have limited effect on cysteinyl leukotriene biosynthesis. In addition, the response to inhaled corticosteroids (ICS) and inhaled long-acting β2-agonists (LABA) combination therapy in moderate to severe persistent asthmatics varies. Additional therapy with leukotriene receptor antagonists (LTRA) in patients with moderate to severe asthma suboptimally controlled with ICS and LABA combination therapy would be complementary to asthma control. Methods: One hundred and ninety eight asthmatics entered a 2 month, open-label descriptive study. Patients suffering from persistent asthma and suboptimally controlled on a combination therapy of fluticasone/salmeterol or budesonide/formoterol were given montelukast 10 mg daily as an add-on therapy. The level of asthma control was assessed using the Asthma Control Questionnaire (ACQ) including FEV1 % predicted at the baseline and after a 2-month treatment with montelukast. A global evaluation of the treatment was also made by the patients and physicians. Results: The mean ACQ score decreased significantly on montelukast (11.5±5.4 at baseline vs. 6.7±5.0), with a significant improvement in all individual symptom scores (p<0.01). The FEV1 % predicted values did not show any significant change. 59.9% of patients and 59.4% of physicians reported global improvement in their asthma (κ=0.85). Conclusion: These results suggest that the addition of montelukast in patients with persistent asthma that is suboptimally contolled by combination therapy of ICS and LABA might confer complementary effects on asthma control.

KW - Asthma control

KW - Inhaled glucocorticosteroid

KW - Long-acting inhaled β2-agonist

KW - Montelukast

UR - http://www.scopus.com/inward/record.url?scp=36148955028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148955028&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:36148955028

VL - 63

SP - 337

EP - 345

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 4

ER -